Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire Perrinjaquet

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Current Opinion in Neurology|March 21, 2019
Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapyClaire Perrinjaquet, Nicolas Desbaillets, Andreas F Hottinger
Revue Medicale Suisse|May 19, 2021
[Immunotherapy for bladder cancer in 2021]Christophe Cisarovsky, Sofiya Latifyan, Claire Perrinjaquet, et al.
Revue Medicale Suisse|May 16, 2019
[Side effects of immune checkpoint inhibitors: diagnosis and management]Claire Perrinjaquet, Maged Zaher, Daniela Aleida Ferraro, et al.
Revue Medicale Suisse|January 28, 2021
[2020 oncology update]Giovanni Dei Tos, Ilianna Galli Vareia, Alexandre Huber, et al.
Revue Medicale Suisse|February 2, 2022
[2021 Oncology update]May-Lucie Meyer, Konstantina Chrysou, Antonia Stamatiou, et al.
Revue Medicale Suisse|January 20, 2023
[Oncology: what's new in 2022]Tu Nguyen-Ngoc, Karim Abdelhamid, Nils Degrauwe, et al.
Health Science Reports|May 15, 2020
Describing adverse events in Swiss hospitalized oncology patients using the Global Trigger ToolAnne Gerber, André Da Silva Lopes, Natacha Szüts, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Current Opinion in Neurology|March 21, 2019
Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapyClaire Perrinjaquet, Nicolas Desbaillets, Andreas F Hottinger
Revue Medicale Suisse|May 19, 2021
[Immunotherapy for bladder cancer in 2021]Christophe Cisarovsky, Sofiya Latifyan, Claire Perrinjaquet, et al.
Revue Medicale Suisse|May 16, 2019
[Side effects of immune checkpoint inhibitors: diagnosis and management]Claire Perrinjaquet, Maged Zaher, Daniela Aleida Ferraro, et al.
Revue Medicale Suisse|January 28, 2021
[2020 oncology update]Giovanni Dei Tos, Ilianna Galli Vareia, Alexandre Huber, et al.
Revue Medicale Suisse|February 2, 2022
[2021 Oncology update]May-Lucie Meyer, Konstantina Chrysou, Antonia Stamatiou, et al.
Revue Medicale Suisse|January 20, 2023
[Oncology: what's new in 2022]Tu Nguyen-Ngoc, Karim Abdelhamid, Nils Degrauwe, et al.
Health Science Reports|May 15, 2020
Describing adverse events in Swiss hospitalized oncology patients using the Global Trigger ToolAnne Gerber, André Da Silva Lopes, Natacha Szüts, et al.
Pageof 1